CLINICAL TRIALS PROFILE FOR LUMIFY
✉ Email this page to a colleague
All Clinical Trials for Lumify
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03782701 ↗ | The Effect of Lumify™ Eyedrops on Eyelid Position | Completed | University of Miami | Phase 4 | 2019-06-18 | The purpose of the research is to see if Lumify™ has an effect on eyelid position. |
| NCT03782701 ↗ | The Effect of Lumify™ Eyedrops on Eyelid Position | Completed | Wendy Lee | Phase 4 | 2019-06-18 | The purpose of the research is to see if Lumify™ has an effect on eyelid position. |
| NCT04007276 ↗ | The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients | Not yet recruiting | Tulane University | Phase 4 | 2025-11-10 | Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lumify
Condition Name
Clinical Trial Locations for Lumify
Trials by Country
Clinical Trial Progress for Lumify
Clinical Trial Phase
Clinical Trial Sponsors for Lumify
Sponsor Name
